MT

Meliora Therapeutics

www.melioratx.com link_icon

Company Research Report: Meliora Therapeutics



Company Overview



  • Name: Meliora Therapeutics

  • Mission: Creating the next generation of precision oncology drugs using machine learning.

  • Founding Information: No information is available.

  • Key People:

  • David Li, CEO and Co-Founder

  • Jason Sheltzer, Scientific Co-Founder

  • Joan Smith, Technical Co-Founder

  • Claudio Chuaqui, SVP of Drug Discovery

  • Anand Selvaraj, Head of Cancer Biology

  • David Jacobson, Data Science Lead

  • Others include Ari Gewirtz, Stephen Sarno, Ashley Gartin, James Lloyd, Peter Sennhenn, and several advisors.

  • Headquarters: No information is available.

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • Known For: Developing oncology drugs using a machine learning-powered approach to understand drug mechanisms of action with greater precision and efficiency.


Products



AnchorOmics Platform


  • Description: A first-of-its-kind atlas mapping drug mechanisms and their impact on cancer biology, capturing drug activity from molecular to organismal levels.

  • Key Features:

  • Utilizes proprietary molecular fingerprinting.

  • Employs advanced machine learning techniques.

  • Facilitates identifying mechanisms of action of therapeutic agents.

  • Combines insights from transcriptomes, methylomes, proteomes, and more into a standardized digital format.

  • Acts as a proprietary prediction engine to identify drug scaffolds and mechanisms of action.


Recent Developments



  • New Products or Features: No specific new products are mentioned, but the platform itself, AnchorOmics, is noted for its novel, mechanism-driven approach.

  • Partnerships: Meliora invites partnerships to leverage its machine learning-based functional genomics for accelerating oncology programs and exploring functional cancer biology.

  • Press Releases and Appointments:

  • March 27, 2023: Appointment of Claudio Chuaqui, Ph.D., as Head of Drug Discovery.

  • October 6, 2022: Raised $11 million for more precise cancer treatments.

  • September 29, 2022: Received $11 million seed financing.


Overall, Meliora Therapeutics is engaged in advancing oncology drug development by leveraging machine learning and comprehensive molecular fingerprinting to create better-targeted cancer therapies. The company is actively seeking partnerships to further its mission of improving therapeutic precision and efficacy.